Alnylam Pharmaceuticals is scheduled to present new clinical data on its ATTR and hypertension drugs at the upcoming European Society of Cardiology (ESC) conference.

An analyst has begun coverage on Alnylam Pharmaceuticals with a bullish outlook, part of the top five stock initiations observed on Wednesday.

Several financial institutions, including Morgan Stanley and Piper Sandler, have raised their price targets for various stocks. Robinhood, in particular, saw its target raised by four banks in eight days, indicating positive outlooks.

Komodo has announced an expansion of its strategic partnership with Alnylam Pharmaceuticals, Inc. This collaboration aims to further advance their joint initiatives in the pharmaceutical sector.

Alnylam has announced the expansion of its RNAi therapeutics reach into four additional Nordic countries, broadening its market presence.

GENESIS Pharma, a biopharmaceutical company, is expanding its long-standing commercial partnership with Alnylam Pharmaceuticals, Inc. to strategically extend its presence into Scandinavia.

Citi has begun coverage of Alnylam Pharmaceuticals (ALNY) with a 'Buy' rating, signaling a positive investment recommendation for the biotech company.

Morgan Stanley has raised its price target for Alnylam Pharmaceuticals, Inc. (ALNY) stock.

Truist has adjusted its price target for Alnylam Pharmaceuticals (ALNY), lowering it from $515 to $505.

Changes to the S&P 500 index are anticipated as Hologic is set for acquisition. Analysts suggest Marvell, Alnylam, and Veeva are leading contenders to join the index as replacements.

Analysts have trimmed their targets for Alnylam Pharmaceuticals, Inc. (ALNY) but maintain faith in the company's growth prospects for 2026.

Kessler Topaz Meltzer & Check, LLP is encouraging investors in Alnylam Pharmaceuticals, Inc. to reach out to the firm, indicating a potential legal inquiry or action related to the company.

Pfizer, Alnylam, and BridgeBio shares saw gains following a late-stage trial setback for AstraZeneca and Ionis.

Alnylam Pharmaceuticals, Inc. (ALNY) and GENESIS Pharma have announced an expansion of their existing commercial partnership.

GENESIS Pharma is extending its collaboration with Alnylam Pharmaceuticals by adding Denmark, Finland, Norway, and Sweden to their existing partnership, which already covers 13 Southeast European markets.

Alnylam Pharmaceuticals has revealed its strategic targets for 2030, emphasizing the role of its drug AMVUTTRA and upcoming pipeline readouts in achieving its long-term goals.

Citi has started coverage on Ionis Pharmaceuticals, Alnylam Pharmaceuticals, and BioMarin Pharmaceutical with a Buy rating, citing positive catalyst and growth outlooks.

Martin Marietta reaffirmed its 2026 adjusted EBITDA guidance, citing ahead-of-schedule integration, while Alnylam reiterated its 2026 TTR sales guidance and expanded clinical trial enrollment.

Key highlights from Alnylam Pharmaceuticals' Q1 earnings call have been released, detailing the company's financial performance and strategic updates.

Analysts are evaluating Alnylam Pharmaceuticals (ALNY) to determine its potential as a leading growth stock.

Alnylam Pharmaceuticals Inc. (ALNY) is highlighted as one of the best high-growth healthcare stocks currently available for investment.

Alnylam Pharmaceuticals stock experienced a significant surge on Monday.

BMO Capital Markets has initiated coverage of Alnylam Pharmaceuticals with an 'outperform' rating, citing the strength of its RNAi pipeline.

An analysis suggests that the recent sell-off of Alnylam Pharmaceuticals stock may be overdone, highlighting factors investors might be overlooking.

Despite reporting its best quarter ever, Alnylam's valuation did not see a corresponding increase, prompting analysis into the reasons behind this market reaction.

An analysis explores the factors that could offer Alnylam Pharmaceuticals (ALNY) sustained long-term growth in the market.

Alnylam Pharmaceuticals (ALNY) and Inceptive have formed a $2 billion partnership aimed at advancing RNAi drug discovery, combining their expertise to develop new therapeutic solutions.

GENESIS Pharma is expanding its collaboration with Alnylam Pharmaceuticals, adding four Scandinavian markets—Denmark, Finland, Norway, and Sweden—to the thirteen markets in Southeast Europe already covered by their partnership.

Alnylam Pharmaceuticals announced a collaboration with Inceptive to leverage artificial intelligence for the development of RNA interference (RNAi) therapies.

Alnylam Pharmaceuticals (ALNY) is being evaluated as one of the leading aggressive growth stocks available for purchase. The analysis suggests it could be a strong contender for investors seeking high-growth opportunities.

Alnylam Pharmaceuticals, Inc. has released a summary of its first-quarter 2026 earnings call, providing insights into its financial results and future projections.

Alnylam Pharmaceuticals announced that its experimental drug for diabetes has progressed to a Phase 2 clinical trial, marking a significant step in its development.

Alnylam Pharmaceuticals has successfully achieved free cash flow breakeven in 2025, marking a significant financial milestone for the company.

Alnylam Pharmaceuticals is targeting a 25% compound annual growth rate (CAGR) through its focus on innovative therapies.

Alnylam Pharmaceuticals has reported a target of $3 billion in revenue for 2025, driven by a 151% surge in its TTR franchise.